Special Issue

Models Analysis for SARS-CoV-2 Transmission and Vaccination Rollout

Message from the Guest Editors

In the three years following the emergence of the global COVID-19 pandemic, the environment and people's daily lives have changed dramatically. Several studies have discussed the correlated factors and potential impacts on human health, contributing to knowledge that has led to the restoration of normal life almost everywhere. Now, the recorded data could be useful in developing innovative models that can describe transmission of the virus with consideration of different global variants and vaccination efficiencies. We believe that existing pandemic data would enable the development of rigid and stable models that can be used to improve protection in potential future pandemics. This Special Issue aims to attract high-quality academic articles that investigate new models and analyze data to provide a better understanding of COVID-19, with emphases on the contribution of vaccination rollout. Studies that consider mathematical, statistical, machine learning, and deep learning models are within the main scope of this Special Issue. We welcome original papers, systematic reviews, and case reports that address topics related to model analysis for SARS□CoV□2 transmission.

Guest Editors

Prof. Dr. Essam A. Rashed

Graduate School of Information Science, University of Hyogo, Kobe 650-0047, Japan

Dr. Sachiko Kodera

Department of Electrical and Mechanical Engineering, Nagoya Institute of Technology, Nagoya 466-8555, Japan

Deadline for manuscript submissions

closed (31 October 2023)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/162133

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI